Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

20117,653 citationsJournal Articlebronze Open Access

Authors

Paul B. Chapman · Memorial Sloan Kettering Cancer Center

Axel Hauschild · Kiel University

Caroline Robert · Institut Gustave Roussy

John B.A.G. Haanen · The Netherlands Cancer Institute

Paolo A. Ascierto · Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

James Larkin · Royal Marsden Hospital

Reinhard Dummer

Abstract

Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).

Topics & Keywords

Melanoma and MAPK Pathways Cutaneous Melanoma Detection and Management Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 364, Issue 26, pp. 2507-2516

DOI: 10.1056/nejmoa1103782

Field-Weighted Citation Impact: 344.08